These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 34070995)

  • 1. Autophagy Induction as a Host-Directed Therapeutic Strategy against
    Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
    Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-Directed Therapeutic Strategies for Tuberculosis.
    Kolloli A; Subbian S
    Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy: A new strategy for host-directed therapy of tuberculosis.
    Paik S; Kim JK; Chung C; Jo EK
    Virulence; 2019 Dec; 10(1):448-459. PubMed ID: 30322337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.
    Wang J; Sha J; Strong E; Chopra AK; Lee S
    Microbiol Spectr; 2022 Oct; 10(5):e0250922. PubMed ID: 36129262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing the mTOR Pathway for Tuberculosis Treatment.
    Singh P; Subbian S
    Front Microbiol; 2018; 9():70. PubMed ID: 29441052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy.
    Ouyang Q; Zhang K; Lin D; Feng CG; Cai Y; Chen X
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32269154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy.
    Kilinç G; Boland R; Heemskerk MT; Spaink HP; Haks MC; van der Vaart M; Ottenhoff THM; Meijer AH; Saris A
    Microbiol Spectr; 2024 Aug; 12(8):e0016724. PubMed ID: 38916320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
    Zumla A; Rao M; Dodoo E; Maeurer M
    BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remembering the Host in Tuberculosis Drug Development.
    Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
    J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
    Dwivedi VP; Bhattacharya D; Singh M; Bhaskar A; Kumar S; Fatima S; Sobia P; Kaer LV; Das G
    J Ethnopharmacol; 2019 Oct; 243():111634. PubMed ID: 30537531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural products in anti-tuberculosis host-directed therapy.
    Huang X; Lowrie DB; Fan XY; Hu Z
    Biomed Pharmacother; 2024 Feb; 171():116087. PubMed ID: 38171242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.